Articles
-
All
-
Scientific Reviews
-
EDM
-
Blog
-
Most Recent
-
Oldest
-
SARS-CoV-2 contains four main structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. All the proteins and subcellular structures of CoVs are promising targets for SARS-CoV-2 research.
-
The concept of ADC can be traced back to the early 1900s, It is a visionary magic bullet that could deliver a toxic drug to certain malignant cells without affecting other normal tissues. Now, it seems that a golden age of ADC drug development is coming.
-
It's has been proved that p53, as a tumor suppressor gene and immune guardian, may become a destroyer through its own mutation. Moreover, the mechanism of p53 was found to be related to ferroptosis. This article mainly explores the mechanism between p53 and ferroptosis in detail.
-
TME (Tumor microenvironment) is considered as a complex integrated system, composed of cellular components such as tumor cells and immune cells, as well as non-cellular components such as ECM and cytokines. According to the spatial distribution of immune cells in TME, "hot" and "cold" TME will be explained in this article.
-
The latest study of Cell magazine "Neural mechanism underlying depressive-like state associated with social status loss" considers social factors as a breakthrough point. It has been found that the downward transition of social status induces depression-like behavior in mice whereas improves the depressive state by restoring their social environment.
-
Necroptosis, also known as necroptosis, is a form of regulated necrotizing cell death mediated by RIP1 and RIP3 kinases. Necroptosis is a process that prevents the self-destruction of activated cells that are blocked by apoptosis. Necroptosis plays a tumor suppressor role in most cases. It may provide benefits in the researches of a variety of human diseases involving immune inflammation and cell death.
-
HLA-E, A Novel Immune Checkpoint
2023-06-29
Immune checkpoints have immunosuppressive functions. It can be used in the research of tumor immunotherapy. In this article, we introduce a new paper entitled "Immune checkpoint HLA-E: CD94 - NKG2Amediates evasion of circulating tumor cells from NK cell surveillance "research paper. -
WHO's Q2 drug list has been updated. Let's take you through the list of the most noteworthy small molecule drugs that we should pay attention to.
-
FDA Approved Drug List!
2023-09-14
In the first half of 2023 (as of June 27), the FDA approved 26 new drugs, let's take you learn about it through the article. -
IHC is an indispensable technique for studying tissue morphology and in situ antigen expression, but usually only one or two antigens in tissues can be stained for analysis. It cannot judge the results more intuitively. Today, Little M will introduce you to the upgraded version mlHC.
-
A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening of diseases such as cancer, infectious diseases, and rare diseases.
-
FDA Annual Review | Record-breaking number of new drug approvals in 2023!
-
KRAS, a gene we've heard so much about, has quickly risen to fame after shedding its "undruggable" label. After reading numerous articles, it's easy to feel overwhelmed and wonder: What exactly should we know about this often-discussed but previously "undruggable" target KRAS?
-
Compound Screening Guide!
2024-03-15
How to use compound library? How to design an experiment if you buy a compound library? Want a specific experimental protocol? This article will introduce popular experimental techniques and provide new ideas for publishing high level literature. -
Wnt/β-catenin and tumor EMT
2024-03-18
Epithelial-Mesenchymal Transition (EMT) is closely related to the plasticity of tumor cells and is a necessary process for tumor metastasis. Wnt/β-catenin is one of the main actors involved in the EMT process. Today, we’re here to popularize the tumor EMT and Wnt/β-catenin pathway~ -
The 2024 AACR meeting concluded successfully in California, USA. Which antitumor drugs stole the show at this conference?
-
Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine in 2023 for their groundbreaking work in nucleoside modification, which paved the way for the creation of successful mRNA vaccines to fight against COVID-19. Let's now delve into the complete process of mRNA vaccine development.
-
Exosomes, which won the Nobel Prize in 2013, are still a research hotspot in the national natural sciences, and their popularity has only increased over the past decade (in 2022, they still rank 5th in the national natural sciences hotspots!). Why have exosomes become the darling of scientific research? Let's take a look together~
-
How important is the compound library? It connects to drug screening on one end and leads to lead compound modifications on the other, serving as one of the sources of new drug development.
-
Antibodies!
2024-07-26
Today, We introduce antibodies for everyone! -
What Are Popular Anti-tumor Drug Targets?
2024-08-20
The rapid development of targeted anti-cancer drugs has spurred diverse research across various modalities. These include small molecules, monoclonal antibodies (mAbs), cell immunotherapies, antibody-drug conjugates (ADCs), and PROTACs (proteolysis targeting chimeras). -
Virtual Screening and New Uses for Old Drugs
2024-09-17
With the advancement of medical science, drug screening against various disease targets has become the fundamental strategy for drug development. Currently, computer-based virtual screening techniques are emerging in the field of new drug research due to their efficiency and low cost. Let's explore it today! -
2024 Nobel Prize Announcements! Curious about the details? Click to dive into the exciting developments!
-
A New Form of Cell Death: PANoptosis!
-
We are thrilled to share the latest advancements in AI technology as highlighted in this insightful article. From groundbreaking innovations to transformative applications, the future of AI is brighter than ever!
-
Advancing Chronic Kidney Disease Research with GJ103 and Lamin B1 Antibody!
-
When you hear "inflammation" and "DNA damage," you might immediately think of disease or injury. However, in brains, these two processes are key steps in forming long-term memories, particularly related to specialized cells in our brain called hippocampal neurons.
-
This article will tell you about the common methods of modeling liver disease in animal models.
-
This article will walk you through the remarkable impacts of anti-payload antibodies, delving into how these molecules are revolutionizing drug development and biological research!
-
This article introduces some common cardiovascular disease models, inducers, modeling protocols and successful modeling cases in the research.
-
Cell Migration vs. Invasion: Differences Revealed by Scratch Assays and Transwell Experiments
2025-05-30
In scientific research, cell migration and invasion are crucial for understanding many important biological processes. This article delves into commonly used detection methods: the scratch assay and Transwell migration/invasion assay. -
How should drug screening experiments be conducted? How can we ensure the accuracy of the lead compounds identified? This article will take you through how MCE's clients conduct drug screening experiments.
-
In this issue, we will conduct an in-depth interpretation from the dimensions of nanoparticle design, mechanism of action, in vivo and in vitro efficacy, and immune regulation, revealing how this research brings new hope for the treatment of invasive tumors through interdisciplinary innovation!
-
IHC, ICC, IF Techniques: A Practical Guide
2025-07-25
Confused About IHC/ICC/IF? Why Does Immunostaining Seem So Complicated? Read This Now! Master Immunostaining with Confidence! -
HTS Breakthroughs Powered by MCE Libraries
2025-08-13
Key High-Throughput Screening Breakthroughs of 2024 Featuring MCE -
Encountering challenges with the high costs and long timelines of drug screening? Have a defined target but remain uncertain how to efficiently identify active molecules? Unsure how to validate hits generated from virtual screening? The ‘Winning Combination’ of drug screening offers a powerful solution to address these critical obstacles.
-
A groundbreaking study in Nature Communications reveals the key mechanism behind Idiopathic Pulmonary Fibrosis and identifies an existing drug with the potential to counter it.
-
This detailed guide outlines the standardized experimental protocols for multiplex immunohistochemistry (mIHC), systematically summarizes common technical issues encountered during sample preparation, staining and imaging processes, and provides practical troubleshooting solutions to ensure reliable and reproducible results in biomedical research and clinical sample analysis.
-
Microglia– the only immune cells within the brain parenchyma. With advancements in imaging technologies, people’s understanding of microglia has shifted from being viewed as 'resting' cells to 'highly active' cells, particularly due to their dynamic processes that seem to be probing surrounding tissues and monitoring neuronal activity. This has made microglia a focal point of research in the field of neuroscience.
-
Exosomes—natural nanoscale carriers—are revolutionizing targeted therapy. This article uncovers the science behind their precision in drug delivery.
-
Cracking the PROTAC Permeability Barrier: CD36-Mediated Endocytosis as a Potential Breakthrough
2025-12-03
This article provides an in-depth analysis of cutting-edge literature revealing CD36 as a key mediator of cellular uptake for PROTACs and bRO5 compounds. By structurally optimizing PROTAC molecules to enhance their affinity for CD36, membrane permeability can be markedly improved, leading to significantly enhanced antitumor efficacy. -
This paper elaborates on cytokines for culturing major immune cells, their regulatory roles, recombinant cytokines' merits and MCE’s related high-quality products.
-
This article walks you through the experimental design and workflow of flow cytometry, delivering a clear, dynamic, and professional overview to elevate your research.
-
Molecular glue degraders have evolved from a serendipitous observation to one of the most dynamic and transformative fields in biomedical research.
-
Research Solution for Breast Cancer TME
2025-05-21
This review examines the complex interactions within the breast cancer tumor microenvironment, emphasizing how understanding these dynamics is essential for developing effective therapies and overcoming immune resistance. -
This review discusses the fundamentals of lipid biology and lipid metabolism, examines dysregulated lipid metabolism in cancer, and summarizes therapeutic strategies targeting lipid metabolic pathways.
-
This review critically examines the role of the JAK-STAT pathway in immunity and autoimmune diseases, reviews current clinical applications of targeted therapies, and highlights emerging trends in autoimmune drug development.
-
This review presents an overview of antibody–drug conjugates from design principles and antitumor mechanisms to structural innovations, clinical progress, and future development prospects.
-
This review summarizes the mechanisms of DSS-induced colitis, commonly used modeling approaches, and key considerations related to DSS molecular weight.
-
This review explores mechanisms and strategies for modulating the gut microbiota to enhance cancer immunotherapy, providing insights to improve therapeutic efficacy.
-
Combating Immune Evasion in Cancer
2025-10-15
This review summarizes the mechanisms by which tumors evade immune surveillance and discusses therapeutic strategies to restore antitumor immunity. -
This review summarizes the mechanisms of drug resistance in triple-negative breast cancer and highlights emerging therapeutic strategies.
-
Bispecific Antibodies in Cancer Therapy
2025-10-29
This review highlights the mechanisms, technology platforms, and clinical progress of bispecific antibodies, and discusses emerging strategies to guide future development. -
This review provides insights into the pancreatic ductal adenocarcinoma tumor microenvironment, highlighting its cellular composition, stromal heterogeneity, and immune-targeting strategies.
-
Understanding In Vivo CAR-T Cell Therapy
2026-01-22
This review provides a comprehensive overview of in vivo CAR-T therapy, covering technical platforms, clinical translation, and key challenges such as gene delivery and immunogenicity. -
Highlight single-cell metabolomics and stable isotope tracing (SIT) in uncovering metabolic heterogeneity and nutrient flux dynamics in tumors.
-
Explore ADC evolution, immune combination strategies, and clinical advances at the intersection of targeted therapy and immunotherapy.
-
Tumor Organoid-Immune Cell Co-Culture Models: Advances, Applications, and Future Directions
2026-05-07
Summarize technical strategies, application advances, and future directions of tumor organoid–immune co-culture systems. -
Review mechanisms, major challenges, and efficacy-enhancing strategies of TCR-T therapy in solid tumors, with implications for future research and clinical translation.
-
The Dual Role of Cellular Senescence in Cancer: Mechanisms, Microenvironment, and Therapeutics
2026-05-21
Explore the dual role of cellular senescence in cancer, including tumor suppression, SASP-driven tumor promotion, senescence heterogeneity and plasticity, and advances in senescence-targeted therapies. -
Review the mechanisms, mitochondrial regulation, disease relevance, and translational opportunities of the NLRP3–STING axis in neuroinflammation.
-
Breaking Immune Resistance in Colorectal Cancer: From Molecular Mechanisms to Precision Therapy
2026-06-25
Explore CRC molecular subtypes, immune landscapes, resistance mechanisms, and emerging precision strategies for improving outcomes across distinct subtypes. -
Explore the mechanisms driving immune tolerance breakdown in autoimmune diseases and emerging tolerance-restoring strategies, with a focus on IL-2-based immune modulation.
-
Explore the mechanisms of tumor immune evasion, dynamic checkpoint regulation, and the evolution of mechanism-driven combinations and patient stratification.
-
Explore how mitochondrial quality control, inflammatory signaling, and metabolic–epigenetic reprogramming regulate cellular senescence and the SASP, along with strategies to restore mitochondrial homeostasis.
-
EC0489, a SMDC for Cancer Therapy
2019-03-25
EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a SMDC under development for the treatment of solid tumours. -
R916562, a dual Axl/VEGF-R2 inhibitor, could be a potential anti-angiogenic and anti-metastatic drug for cancer chemotherapy.
-
Role of PRMT7 Probe SGC3027 in Cancer
2019-03-27
SGC3027 is the first potent, selective and cell active chemical probe for PRMT7. SGC3027 is also a pro-drug, which converts to the active compound SGC8158 -
Alofanib, An Allosteric Inhibitor of FGFR2
2019-03-28
Alofanib is an allosteric inhibitor of FGFR2 and inhibits FGF-mediated proliferation with GI50s of 16-370 nM, showing pronounced antitumor activity. -
A Novel and Efficacious RAF Inhibitor RAF709
2019-03-30
RAF709, a novel and efficacious RAF inhibitor, activates the MAPK pathway and shows antitumor activity in tumor cells harboring BRAF or RAS mutations. -
CF53 is a highly potent, selective and orally active inhibitor of BET protein, with anti-tumor activity in acute leukemia and breast cancer cell lines.
-
AZD3229 is a Potent Pan-KIT Mutant Inhibitor
2019-04-04
AZD3229 is a potent, pan-KIT mutant inhibitor with potent single digit nM growth inhibition against a diverse panel of mutant KIT driven Ba/F3 cell lines. -
BR351 is a Brain Penetrant MMP Inhibitor
2019-04-05
BR351 is a brain penetrant MMP inhibitor, and a potential tool for the molecular imaging of activated MMPs with PET, with an IC50 in the nanomolar range. -
A Lead PROTAC BRD9 Chemical Degrader
2019-04-06
PROTAC BRD9 Degrader-1 is a lead PROTAC BRD9 chemical degrader and a selective probe useful for the study of BAF complex biology. -
SGC-GAK-1 is a potent, selective, and cell-active GAK inhibitor and shows potent anti-proliferative activity in LNCaP and 22Rv1 cells.
-
COH000 is an allosteric, covalent and irreversible inhibitor of SUMO-activating enzyme, with an IC50 of 0.2 μM for SUMOylation in vitro.
-
HS-1371 is a Small Molecule RIP3 Inhibitor
2019-04-09
HS-1371 is a novel kinase inhibitor of RIP3-mediated necroptosis, showing an inhibitory effect on S227 auto-phosphorylation of RIP3 at the basal level. -
MK-0429 is An Oral Integrin (αvβ3) Inhibitor
2019-04-11
MK-0429, an orally active αvβ3 inhibitor, is a potential therapeutic agent for the prevention of kidney fibrosis, melanoma and osteoporosis. -
AZ304, a Dual BRAF Inhibitor Against Cancer
2019-04-12
AZ304 is a potent BRAF inhibitor, blocks both wild type BRAF and V600E mutant BRAF activity, with IC50s in the nanomolar range. -
Erteberel is a Selective ERβ Agonist
2019-04-16
Erteberel (LY500307) is a synthetic, nonsteroidal estrogen which acts as a selective ERβ agonist and under development for the treatment of schizophrenia. -
MBQ-167 is a dual Rac/Cdc42 inhibitor in in metastatic cancer, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.
-
PRN1008 is a Reversible Covalent and Oral Active Inhibitor of Bruton’s Tyrosine Kinase (BTK)
2019-04-18
PRN1008 is a selective, reversible covalent and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 1.3 nM. -
Multiple Tyrosine Kinases Inhibitor TAS-115
2019-04-19
TAS-115 is a potent VEGFR and c-Met/HGFR-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. -
Y06036 is a potent and selective BET inhibitor for potential treatment of castration-resistant prostate cancer. With nanomolar inhibition.
-
JNJ-64619178 is a selective and pseudo-irreversible PRMT5 inhibitor with an IC50 of 0.14 nM. Has potent Activity In Lung Cancer.
-
(E)-AG 99 is an EGFR inhibitor and shows a growth-inhibition on not only serum-starved cells but also normally grown cells. Treatment for Bladder cancer.
-
TAK-828F is a potent, selective and orally active retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist. TAK-828F inhibits IL-17A cytokine expression and reduces symptoms of autoimmune encephalomyelitis mice.
-
Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM. Antitumor activity.
-
Borussertib is a covalent-allosteric and first-in-class inhibitor of protein kinase Akt, with an IC50 of 0.8 nM and a Ki of 2.2 nM for Akt-wt.
-
NRX-252262 is a β-catenin:β-TrCP interaction enhancer, and its cognate E3 ligase, SCFβ-TrCP, induces mutant β-catenin degradation, with an EC50 of 3.8 nM
-
TAK-981 is a selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities
-
TD-428 is a Highly Specific BRD4 Degrader
2019-04-29
TD-428, a immunomodulatory drug analog, is a highly specific BRD4 degrader with a DC50 of 0.32 nM. TD-428 reduces c-Myc levels more efficiently than JQ1. -
SLLN-15 is an oral activ enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC).
-
A1874 is a nutlin-based and BRD4-degrading PROTAC with a DC50 of 32 nM. Effective in inhibiting many cancer cell lines proliferation
-
BAY-8002 is a selective and orally active inhibitor of monocarboxylate transporter 1 (MCT1), with an IC50 of 85 nM. Has potential to treat lymphoma.
-
MRTX-1257 is a selective, irreversible, covalent and oral active KRAS G12C inhibitor, with an IC50 of 900 pM for KRAS dependent ERK phosphorylation.
-
USL311 is a selective CXCR4 antagonist, which prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4. Anti-tumor activity.
-
TX1-85-1, a ATP-competitive ligand of Her3, covalent modification of Her3 to inhibit Her3 signaling
2019-06-01
TX1-85-1 is a Her3 (ErbB3) inhibitor with an IC50 of 23 nM. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling. -
IWP-O1, a Highly Potent Porcupine Inhibitor, Functions by Preventing the Secretion of Wnt Proteins
2019-06-03
IWP-O1 is a Porcupine (Porcn) inhibitor, with an EC50 of 80 pM in L-Wnt-STF cells. IWP-O1 functions by preventing the secretion of Wnt proteins[ -
GSK3145095 is a RIP1 kinase inhibitor with an IC50 of 6.3 nM. Potently blocks the TNF response and RIP1-dependent inflammatory cytokine MIP-1β production.
-
PF-06465469 is a Covalent Inhibitor of ITK
2019-06-08
PF-06465469 is a potent and covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 inhibits MEK1/2 or AKT phosphorylation. -
JMS-17-2 is a CX3CR1 Antagonist
2019-06-12
JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. Has potential to treat cancers such as breast cancer. -
BAY-11-7082 inhibits the proliferation and induces the apoptosis of U266 cells through inhibiting NF-κB pathway. BAY 11-7082 ameliorates experimental diabetic neuropathy by modulating neuroinflammation and improving antioxidant defence.
-
S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt). S18-000003 ameliorates psoriasis-like lesions in vivo. S18-000003 can be used for the research of skin inflammatory diseases.
-
PTC299 is a dual and orally active DHODH and VEGF inhibitor, has broad and potent activity against hematological cancer cells.
-
AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3). AMG 487 has potential to treat metastatic cancer.
-
TPCA-1, a Direct Dual Inhibitor of STAT3 and NF-κB, Regresses Mutant EGFR-Associated NSCLC
2019-07-15
TPCA-1 is a potent and selective inhibitor of IKK-2 with IC50 of 17.9 nM. TPCA-1 is an effective inhibitor of STAT3 phosphorylation, DNA binding. -
FGTI-2734 is a dual farnesyl and geranylgeranyl transferase-1 inhibitor. FGTI-2734 prevents membrane localization of KRAS and mutant KRAS pancreatic tumors.
-
BI-882370 is a potent RAF kinase inhibitor with IC50s of 0.4, 0.8, and 0.6 nM for oncogenic BRAFV600E-mutant, the WT BRAF and CRAF kinases , respectively.
-
MSX-122 is an orally active partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions. MSX-122 has both anti-tumor and anti-metastasis activities.
-
ZT-12-037-01 is a ATP-competitive and specific STK19 inhibitor and inhibits oncogenic NRAS-driven melanocyte malignant transformation.
-
PT2977 is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. PT2977 is a potential treatment for ccRCC and VHL disease.
-
BI-2852 is a potent KRAS inhibitor with nanomolar affinity and reduces pERK and pAKT levels in a dose-dependent manner in a KRAS mutant cell line NCI-H358.
-
BAY-293 is a potent inhibitor of Son of Sevenless 1 (SOS1) and blocks RAS activation via disruption of the KRAS-SOS1 interaction with an IC50 of 21 nM.
-
WZ811 is an Orally Active CXCR4 Antagonist
2019-09-07
WZ811 is an orally active, highly potent competitive antagonist of CXCR4, which inhibits chronic lymphocytic leukemia progression and tumorigenesis. -
RU-302 is a pan-TAM inhibitor that blocks the TAM Ig1 ectodomain and the Gas6 Lg domain interaction. RU-302 blocks Gas6-inducible Axl receptor activation.
-
BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor and sensitizes apoptosis by in breast cancer.
-
BI-167107 is a high affinity, full agonist that binds to the β2 adrenergic receptor (β2AR) with a dissociation constant Kd of 84 pM.
-
IPR-803 is a potent inhibitor of the uPAR•uPA protein-protein interaction, and binds directly to uPAR with sub-micromolar affinity.
-
Vorolanib is an orally active, multikinase VEGF/PDGF receptor inhibitor with antitumor activity and is expected to disrupt tumor angiogenesis.
-
CCG-222740 is a potent and selective MRTF pathway inhibitor. It effectively reduces fibrosis in the skin and blocks melanoma metastasis.
-
IACS-8803 is a highly potent cyclic dinucleotide stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy.
-
AC-73 is a first specific, orally active the cluster of differentiation 147 (CD147) inhibitor and specifically disrupts CD147 dimerization.
-
UK 356618 is a Selective MMP-3 Inhibitor
2019-12-25
UK 356618 is a selective and potent inhibitor of MMP-3. UK 356618 exhibits potent anti-inflammatory and anti-cancer activity. -
CH6953755 is a potent, orally active and selective YES1 kinase inhibitor leading to antitumor activity against YES1 Gene -amplified cancers.
-
CA-4948 is a Selective and Orally Bioavailable IRAK4 Kinase Inhibitor for Lymphoma Treatment
2020-01-05
CA-4948 is a potent, selective and orally bioavailable IRAK4 kinase inhibitor. CA-4948 can be used for the treatment of lymphoma. -
BAY-985 is an orally active and selective ATP-competitive dual inhibitor of TBK1 and IKKε with IC50s of 2/30 and 2 nM for TBK1 and IKKε, respectively.
-
ADH-503 is an orally active and allosteric CD11b agonist and leads to the repolarization of tumor-associated macrophages.
-
Balixafortide is a potent, selective peptidic CXCR4 antagonist with anti-cancer effects, and blocks β-arrestin recruitment and calcium flux.
-
CCT365623, an Orally Active LOX Inhibitor, Supresses EGFR (pY1068) and AKT Phosphorylation
2020-04-16
CCT365623 is an orally active LOX inhibitor, suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 has good pharmacokinetic properties. -
RBN-2397 is an orally active accross species NAD+ competitive inhibitor of PARP7. RBN-2397 binds to PARP7 and restores interferon (Type I) signaling.
-
GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor. GSK143 reduces inflammation in the intestinal muscularis in mice.
-
EW-7195 is a potent and selective ALK5 inhibitor, and efficiently inhibits TGF-β1-induced Smad signaling, EMT and breast tumour metastasis to the lung.
-
CAY10404 is a potent and highly selective COX-2 inhibitor. CAY10404 is a potent inhibitor of PKB/Akt and MAPK signalling pathways.
-
MSA-2 is an orally available non-nucleotide STING agonist. MSA-2 shows antitumor activity and stimulates interferon-β secretion in tumors.
-
SP-8356, an orally active CD147inhibitor, exerts anti-breast cancer effects by inhibiting NF-κB signaling. Anti-atherosclerotic effects.
-
CB-1158, a potent and orally bioavailable inhibitor of arginase, blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
-
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses effective anti-tumor activity in vitro and in vivo.
-
Verucopeptin inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Also a potent HIF-1 inhibitor.
-
E7820, sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
-
Cyclo(-RGDfK) is a selective inhibitor of the αvβ3 integrin. Cyclo(-RGDfK) potently targets cancer cells through binding to the cell surface αvβ3 integrin.
-
Cilengitide is a compound targeting angiogenesis, the cornerstone of tumor growth and metastasis. ανβ3 and ανβ5 are the target of Cilengitide.
-
Tetrac inhibits the cellular actions of thyroid hormone initiated at the hormone receptor on plasma membrane integrin alphavbeta3.
-
BMS-P5 is an Orally Active PAD4 Inhibitor
2020-12-12
BMS-P5 is an orally active PAD4 inhibitor. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model -
ML132, a potent and selective caspase 1 inhibitor with a unique selectivity pattern, is responsible for the proteolytic activation of IL-1β and IL-18.
-
ENMD-1198 is an orally active microtubule-targeting agent with antiproliferative and antiangiogenic activity.
-
CC-90001 is a potent, selective, and orally active inhibitor of JNK. CC-90001 can be used for the research of idiopathic pulmonary fibrosis (IPF).
-
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM).
-
FAPI-46 is a quinoline-based FAP-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation.
-
SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist. SB-332235 inhibits acute and chronic models of arthritis in the rabbit.
-
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction. It induces high levels of IL-2.
-
ML339 is a Selective CXCR6 Antagonist
2021-05-12
ML339 is a small molecule antagonist would block Prostate cancer cell trafficking; hence mediate a metastatic event and disease progression. -
Sitravatinib (MGCD516) is an Orally Bioavailable RTK Inhibitor with PD-1 Blockade Activity
2021-06-03
Sitravatinib, a small molecule RTK inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. -
Motesanib (AMG 706) is an orally active VEGFR inhibitor. Potently inhibits angiogenesis and induces regression in tumor xenografts.
-
EMD527040 is a highly selective αvβ6 antagonist with antifibrotic activities.
-
Lumiracoxib is a COX-2 inhibitor. Lumiracoxib acts as nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities.
-
Inupadenant is an orally active, highly selective A2A receptor antagonist with potent anti-tumor activity.
-
UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with anti-cancer activity.
-
Ruxolitinib is a potent and selective JAK1/2 inhibitor and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy.
-
AZD4635 is a potent, selective and orally active antagonist of A2AR that reverses adenosine-mediated immune suppression.
-
Nintedanib a potent and orally active triple vascular kinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β.
-
IMD-0354 is a Selective IKKβ Inhibitor
2021-11-09
IMD-0354 is a selective IKKβ inhibitor and potently inhibits NF-κB activity. IMD0354 has antitumor activity. -
Axitinib is a multi-targeted tyrosine kinase inhibitor and potently inhibitor VEGFR1, VEGFR2, VEGFR3 and PDGFRβ.
-
CL097 is a TLR7/8 agonist. CL097 induces pro-nflammatory cytokines. CL097 induces NADPH oxidase priming and efficient diabetogenic cytotoxic T lymphocyte (CTL) function in NOD mice.
-
Zingerone is a natural orally active nontoxic methoxyphenol potent anti-inflammatory, antidiabetic, antioxidize, and anti-tumor properties.
-
Indoximod, an immunometabolic adjuvant, is an orally active IDO pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR.
-
Tanomastat is an orally active, non-peptidic biphenyl MMPs inhibitor, with antiangiogenic, anti-invasive and antimetastatic activities.
-
BM213 is a selective C5aR1 agonist. It’s a useful research tool to study C5aR1 function
-
Telatinib is an orally active inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit.
-
Marimastat (BB2516) is a broad spectrum and orally bioavailable inhibitor of MMPs (Matrix metalloproteinases).
-
Gardiquimod is a TLR7/8 agonist and can inhibit HIV-1 infection.
-
Vatalanib is an inhibitor of VEGFR2/KDR. Vatalanib induces inhibition of the angiogenic response to VEGF and PDGF.
-
Toceranib is a selective and orally active inhibitor of RTK and has the potential for the research of canine mast cell tumors.
-
Tiragolumab is an immune checkpoint inhibitor binding to TIGIT. Tiragolumab is effective against multiple solid malignancies.
-
Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities.
-
KGP94 is a selective inhibitor of cathepsin L. KGP94 has antitumor activity and improves survival of bone metastases bearing mice.
-
Pelecopan is a potent, selective, and orally active complement factor D inhibitor, possessing the potential to study paroxysmal nocturnal hemoglobinuria (PNH).
-
Certepetide is a Tumor-penetrating Enhancer via RGD Motif Interaction with Alphav-integrins
2022-09-01
Certepetide is a tumor-penetrating enhancer and has the potential for the research of metastatic pancreatic ductal adenocarcinoma. -
BSP16 is a potent, orally active stimulator of interferon genes (STING) agonist. BSP16 has potent anti-cancer activity.
-
Parsatuzumab (RG 7414) is a humanized monoclonal antibody, that acts as an immunomodulator, and binds to EGFL7.
-
Etrolizumab is a Gut-selective, Anti-β7 Integrin McAb for Inflammatory Bowel Disease (IBD) Research
2022-11-05
Etrolizumab is a gut-selective, anti-β7 integrin monoclonal antibody and has the potential for the research of inflammatory bowel disease. -
Serplulimab is a humanized monoclonal anti-PD-1 antibody and has the potential for the research of small cell lung cancer.
-
ABT-510, a peptide analog of thrombospondin-1 (TSP-1), can block angiogenesis in vitro and in vivo, and slow tumor growth.
-
Mogamulizumab is an Anti-CCR4 monoclonal antibody. It enhances antibody-dependent cellular cytotoxicity and is effective against leukemia.
-
Bapotulimab (BAY-1905254) is an ILDR2 IgG antibody that blocks the immunosuppressive effects of ILDR2 on T-cell activation.
-
Nanrilkefusp alfa is a selective and strong IL-15 agonist. It inhibits tumor metastasis and viability by activating natural killer (NK) cells.
-
Urabrelimab (SRF231) is an anti-CD47 monoclonal antibody, blocking the CD47-SIRPα interaction. It has the potential to research anticancer.
-
Efineptakin alfa (NT-17) is a Long-Acting Recombinant Human IL-7 for Glioblastoma Research
2023-02-07
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa can be used for glioblastoma research. -
Pegdinetanib (BMS-844203) is a selective VEGFR-2 inhibitor with antitumor activity.
-
Tifcemalimab, a Humanized anti-BTLA monoclonal antibody, blocks the interaction of HVEM-BTLA by binding to BTLA and activates lymphocytes.
-
Geptanolimab (CBT-501) is a programmed death-1 (PD-1) monoclonal antibody. Geptanolimab can be used in research forsolid tumor research.
-
Dazostinag is a STING Agonist and Can be used for Antibody-Drug Conjugates (ADCs) Synthesis
2023-03-13
Dazostinag is a STING agonist and a playload, to synthesis antibody-drug conjugates (ADCs). It has antitumor activity in vivo. -
Ruxolitinib is an orally-active JAK1/2 inhibitor. Ruxolitinib has the potential for the research of myeloproliferative neoplasm (MPN).
-
BBO-11818 is a potent, selective, orally bioavailable, and noncovalent pan-KRAS inhibitor targeting multiple clinically relevant KRAS mutants in both ON and OFF states.
Products
-
All
-
Inhibitors & Agonists
-
Isotope-Labeled Compounds
-
Fluorescent Dye
-
Peptides
-
Screening Libraries
-
Inhibitory Antibodies
-
Reference Standards
-
GMP Small Molecules
-
Enzyme
-
Biochemical Assay Reagents
-
Natural Products
| Cat. No. | Product Name | Information | Application | Publication |
|---|---|---|---|---|
| HY-10219 | Rapamycin |
Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin is a molecular glue that binds FKBP12 and mTOR proteins together, thereby inhibiting mTOR kinase activity. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant.
Source: Streptomyces hygroscopicus |
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Bacterial Infection
Fungal Infection
Pain
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
SARS-CoV-2 Infection
Obesity
Lung Fibrosis
|
1470
|
| HY-100523 | ML385 |
ML385 is a potent and selective Nrf2 inhibitor with an IC50 of 1.9 μM. ML385 directly binds to the Neh1 domain of NRF2, interferes with the binding of the MAFG-NRF2 protein complex to the antioxidant response element (ARE) DNA sequence, thereby blocking the expression of downstream target genes of NRF2. ML385 can be used in studies related to adult T-cell leukemia, breast cancer, myocardial ischemia/reperfusion injury, non-small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and lung squamous cell carcinoma.
|
Breast Cancer
Colorectal Cancer
Cardiovascular Disease
Non-Small Cell Lung Cancer
Lung Squamous Cell Carcinoma
Squamous Cell Carcinoma
Esophageal Cancer
|
644
|
| HY-10071 | Y-27632 |
Y-27632 is a ROCK inhibitor with Ki values of 220 nM and 300 nM for ROCK1 and ROCK2, respectively. Y-27632 exerts anti-inflammatory and immunomodulatory effects in systemic lupus erythematosus models by inhibiting the ROCK/NF-κB pathway. Y-27632 enhances autophagy by inhibiting the AKT/mTOR pathway, thereby inducing apoptosis apoptosis in oral squamous cell carcinoma. Y-27632 induces the formation of tunneling nanotubes in ARPE-19 cells and significantly enhances mitochondrial transfer through these channels. Y-27632 promotes neurite outgrowth in PC12 cells by activating the Rac1/NOX1/ROS/AKT/PAK1 signaling cascade.
|
|
602
|
| HY-15760 | Necrostatin-1 |
Necrostatin-1 (Nec-1) is a potent and cross the blood-brain barrier necroptosis inhibitor with an EC50 of 490 nM in Jurkat cells. Necrostatin-1 inhibits RIP1 kinase (EC50=182 nM). Necrostatin-1 is also an IDO inhibitor.
|
|
575
|
| HY-10358 | MK-2206 dihydrochloride |
MK-2206 dihydrochloride (MK-2206 2HCl) is an orally active pan-AKT inhibitor, with IC50 values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 dihydrochloride inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 dihydrochloride induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 dihydrochloride causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 dihydrochloride can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia.
|
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Large Cell Lung Carcinoma
Metastatic Breast Cancer
Lung Fibrosis
|
494
|
| HY-13966 | 2-Deoxy-D-glucose |
2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on hexokinase.
|
|
390
|
| HY-B0795 | MHY1485 |
|
223
|
|
| HY-17471A | Metformin hydrochloride |
Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo.
|
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Digestive System Inflammation
Cardiovascular Disease
Glucose Metabolism
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
Large Cell Lung Carcinoma
HER-2 Positive Breast Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
SARS-CoV-2 Infection
Parkinson's Disease
Chronic Pain
Obesity
|
212
|
| HY-B0627 | Metformin |
Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo.
|
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Pain
Digestive System Inflammation
Cardiovascular Disease
Glucose Metabolism
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
Large Cell Lung Carcinoma
HER-2 Positive Breast Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
Parkinson's Disease
Obesity
Lung Fibrosis
|
212
|
| HY-13003 | Torin 1 |
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Pain
Obesity
Lung Fibrosis
|
140
|
|
| HY-10218 | Everolimus |
Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective, orally active, blood-brain barrier-permeable mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities.
|
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Bacterial Infection
Pain
Digestive System Inflammation
Non-Small Cell Lung Cancer
Luminal Breast Cancer
HER-2 Positive Breast Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
Cytomegalovirus Infection
SARS-CoV-2 Infection
Obesity
Lung Fibrosis
|
125
|
| HY-108331 | 3-TYP |
3-TYP is an inhibitor of SIRT3 (IC50of 38 μM) and an inhibitor of Methionine Adenosyltransferase (MAT) 2 and Indoleamine 2,3-Dioxygenase (IDO). There may be many off-target sites for 3-TYP that need to be examined, such as NAD-dependent enzymes, including dehydrogenases.
|
|
109
|
| HY-L025 | Anti-Cancer Compound Library |
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc.
MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.
|
|
100
|
| HY-L031 | Small Molecule Immuno-Oncology Compound Library |
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.
MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.
|
|
88
|
| HY-L058 | Glycolysis Compound Library |
Glycolysis is a series of metabolic processes by which one molecule of glucose is catabolized to two molecules of pyruvate with a net gain of two ATP. Glycolysis takes place in 10 steps and catalyzed by a series of enzyme, such as hexokinase, Glucose-6-phosphate isomerase, Phosphofructokinase, etc. Glycolysis is used by all cells in the body for energy generation.
Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply. This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation. Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications.
MCE provides a unique collection of 1,379 glycolysis compounds that mainly target hexokinase, glucokinase, enolase, pyruvate kinase, PDHK, etc. MCE Glycolysis Compound Library is a useful tool for glucose metabolism research and anti-cancer drug discovery.
|
|
86
|
| HY-L092 | Glucose Metabolism Compound Library |
Glucose homeostasis is tightly regulated to meet the energy requirements of the vital organs and maintain an individual’s health. Glucose metabolism includes glycolysis, tricarboxylic acid cycle, pentose phosphate pathway, oxidative phosphorylation and other metabolic pathways. Glucose is the major carbon source that provides the main energy for life. Glucose metabolism dysregulation is also implicated in many diseases such as diabetes, heart disease, neurodegenerative diseases and even cancer.
MCE offers a unique collection of 1,777 compounds related to glucose metabolism, which target glucose metabolism related targets, such as GLUT, Hexokinase, Pyruvate Kinase, IDH, etc. MCE glucose metabolism library is a powerful tool for studying glucose metabolism and drug discovery of diseases related to glucose metabolism.
|
|
85
|
| HY-L075 | Anti-Lung Cancer Compound Library |
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.
As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.
MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.
|
|
84
|
| HY-L083 | Anti-Cancer Metabolism Compound Library |
Mutations in oncogenes and tumor suppressor genes can modify multiple signaling pathways and in turn cell metabolism, which facilitates tumorigenesis. The paramount hallmark of tumor metabolism is “aerobic glycolysis” or the Warburg effect, coined by Otto Warburg in 1926, in which cancer cells produce most of energy from glycolysis pathway regardless of whether in aerobic or anaerobic condition. Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside. The increased uptake of glucose is facilitated by the overexpression of several isoforms of membrane glucose transporters (GLUTs). Likewise, the metabolic pathways of glutamine, amino acid and fat metabolism are also altered. Recent trends in anti-cancer drug discovery suggests that targeting the altered metabolic pathways of cancer cells result in energy crisis inside the cancer cells and can selectively inhibit cancer cell proliferation by delaying or suppressing tumor growth.
MCE provides a unique collection of 3,806 compounds which cover various tumor metabolism-related signaling pathways. These compounds can be used for anti-cancer metabolism targets identification, validation as well anti-cancer drug discovery.
|
|
84
|
| HY-L146 | Metabolic Enzyme Compound Library |
Metabolism is the set of life-sustaining chemical reactions in organisms that maintain cell homeostasis. Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of molecules including glucose metabolism, lipid metabolism and amino acid or protein metabolism within a cell or tissue. As catalysts, enzymes are crucial to metabolism as they allow a reaction to proceed more rapidly and tregulate the rate of a metabolic reaction. Due to the importance of metabolic balance in the organism, the abnormal function of metabolic enzymes often leads to the occurrence of a variety of metabolic diseases, such as diabetes, obesity, cardiovascular disease, etc.
MCE designs a unique collection of 4,407 metabolic enzymes related small molecules, which is an important tool for studying the metabolic activities of organisms and developing drugs for metabolic diseases.
|
|
84
|
| HY-L064 | Glutamine Metabolism Compound Library |
Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.
Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.
MCE owns a unique collection of 1,827 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.
|
|
83
|
| HY-L079 | Anti-Blood Cancer Compound Library |
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.
Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.
MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.
|
|
83
|
| HY-L133 | Cuproptosis Compound Library |
Copper is an important co-factor of all biological enzymes, but if the concentration exceeds the threshold of maintaining the homeostasis mechanism, copper will lead to cytotoxicity. This death mechanism has been named "Cuproptosis".
The mechanism of cuproptosis distinct from all other known mechanisms of regulated cell death, including apoptosis, pyroptosis, necroptosis, and ferroptosis.
Copper combine with the lipoylated components of the tricarboxylic acid cycle (TCA), leading to lipoylated protein aggregation and subsequent loss of iron-sulfur cluster proteins, ultimately resulting in protein toxicity stress and cell death. Studies have shown that the necessary factors for cuproptosis include the presence of glutathione, mitochondrial metabolism of galactose and pyruvate, and glutamine metabolism.
Targeted regulation of cuproptosis is a potential choice to treat cancer, rheumatoid arthritis, and other diseases. For example, up-regulation of LIPT1 may inhibit the occurrence and development of tumors by destroying TCA in mitochondria and then inducing cuproptosis.
MCE supplies a unique collection of 446 cuproptosis-related compounds, all of which act on the targets or signaling pathways related to cuproptosis and may have in inhibitory or activated effect on cuproptosis. MCE Cuproptosis Library is a useful tool for drug research related to cancer, rheumatoid arthritis, and other diseases.
|
|
83
|
| HY-L204 | Lactic Acid Metabolic Compound Library |
Lactic acid metabolism is one of the key metabolic pathways within living organisms. It plays a crucial role not only in cellular energy conversion but is also closely related to a variety of physiological and pathological processes. The production and clearance of lactic acid are important indicators of cellular metabolic balance, and its abnormal regulation may lead to conditions such as lactic acidosis, muscle fatigue, and hereditary metabolic diseases. Moreover, lactic acid is closely related to the malignancy of tumors and is considered a biomarker for malignant tumors and poor prognosis. Lactic acid can serve as a metabolic substrate to support the metabolic needs of tumor cells under hypoxic conditions, and it can also cause acidification of the tumor microenvironment, suppress immune cell function to promote immune evasion, and induce drug resistance in tumor cells. Currently, targeting lactic acid-lactylation and its related metabolic pathways has become a new research avenue for cancer treatment. In-depth exploration of the molecular mechanisms of lactic acid metabolism can help in screening lead compounds that regulate the lactic acid metabolism.
MCE contains 582 small molecule compounds targeting enzymes involved in lactic acid metabolism. This library is of significant value for researching the role of lactate metabolism in the mechanisms of diseases.
|
|
83
|
| HY-L213 | Anti-Cancer Approved Drug Library |
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies.
This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment.
MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
|
|
83
|
| HY-L227 | Amino Acid Metabolite Compound Library |
Amino acids are the fundamental components that sustain life activities, playing roles in ATP generation, promoting nucleotide synthesis, and maintaining cellular redox balance. Moreover, dysregulation of amino acid consumption is a significant potential regulatory mechanism leading to impaired anti-tumor immunity in immune cells. The normal functioning of immune cells relies on amino acid metabolic pathways to obtain energy and materials, and upon activation, they reprogram their metabolism to support growth, proliferation, and effector functions. Additionally, metabolic disorders of specific amino acids (such as branched-chain amino acids, glutamine, and arginine) can exacerbate mitochondrial dysfunction and oxidative stress, thereby promoting myocardial fibrosis and cardiac cell damage. Therefore, conducting research related to amino acid metabolism holds promise for discovering potential drugs for diseases related to cancer, immunity, and metabolism.
MCE can provide 195 kinds of metabolites of amino acid metabolic pathways, which can be used for drug screening in various diseases such as cancer, immune disorders, metabolic diseases, mitochondrial-targeted diseases
|
|
83
|
| HY-L234 | Nucleotide Metabolite Compound Library |
Nucleotide metabolism is central to cancer aggressiveness, underpinning uncontrolled proliferation, chemotherapy resistance, immune evasion, and metastasis. It is transcriptionally regulated by oncogenes (e.g., MYC) and tumor suppressors (e.g., pRb). Nucleotide imbalance and nucleoside degradation further regulate cell state transitions, especially following replication stress. Additionally, secretion of nucleotides/nucleosides into the tumor microenvironment modulates immune responses and influences treatment efficacy. Therefore, nucleotide metabolites have roles in disease response and indication in cancer research, and can be utilized to develop cancer-related mechanisms and drugs.
MCE can provide 83 metabolites produced by nucleotide metabolic pathways, which can be used for disease mechanism research and drug research.
|
|
83
|
| HY-L250 | Lactic Acid Metabolite Compound Library |
In the progression of various diseases, metabolic reprogramming has emerged as a key hallmark. Lactate, as an important metabolic signaling molecule, is widely involved in tumorigenesis, immune regulation, and inflammatory responses. Particularly within the tumor microenvironment, the abnormal accumulation of lactate not only affects cellular energy metabolism but also promotes disease progression by modulating immune cell functions and mediating protein lactylation, thereby participating in epigenetic regulation and signaling networks. Therefore, systematic investigation of lactate metabolic pathways and their associated metabolites is of great significance for understanding disease mechanisms and developing novel therapeutic strategies.
The MCE lactic acid metabolite compound library contains 61 compounds and is constructed around key metabolic pathways involving lactate production, transport, and utilization. This library systematically includes core intermediates from glycolysis, the tricarboxylic acid (TCA) cycle, and the lactate cycle. Focusing on disease-associated metabolic reprogramming, it is suitable for research in oncology, inflammation, and metabolic disorders. The library can be used to elucidate the roles of lactate in tumor microenvironment regulation, immune evasion, and epigenetic modifications (such as protein lactylation). In addition, it provides high-quality small-molecule resources for drug screening, facilitating the discovery of potential modulators targeting key enzymes (such as LDH) or transporters (such as MCTs) involved in lactate metabolism.
|
|
83
|
| HY-L252 | Carbohydrate Metabolite Compound Library |
Carbohydrate metabolism serves as a central hub for energy supply and biosynthesis in living organisms and plays a critical role in the onset and progression of various diseases. In recent years, studies have shown that tumor cells reprogram their energy metabolism through aerobic glycolysis (the Warburg effect) to support rapid proliferation. Immune cells also rely on specific carbohydrate metabolic pathways to regulate their activation and differentiation states, while disorders such as diabetes and metabolic syndrome arise directly from dysregulation of carbohydrate metabolism. In addition, enzymes and key metabolic nodes involved in carbohydrate metabolism have become important targets for drug discovery, and therapeutic strategies targeting glycolysis, the pentose phosphate pathway, and energy metabolism are continuously advancing the treatment of cancer and metabolic diseases. Therefore, systematic analysis of carbohydrate metabolic networks and their associated metabolites is of great significance for elucidating disease mechanisms and developing novel therapeutic approaches.
The MCE Carbohydrate Metabolism Metabolite Library is constructed based on classical carbohydrate metabolic pathways and contains 76 metabolites. It systematically integrates key metabolic networks, including glycolysis, the pentose phosphate pathway, the tricarboxylic acid (TCA) cycle, monosaccharide metabolism, and sugar acid interconversions. The library comprehensively covers core metabolic nodes from glucose uptake and utilization to energy production and biosynthesis, while also incorporating important upstream and downstream intermediates. It enables accurate representation of intracellular metabolic flux dynamics and is well suited for applications such as metabolic flux analysis, target validation, and mechanistic studies. Furthermore, it provides robust support for multi-omics integration and the development of precision intervention strategies.
|
|
83
|
| HY-L948 | PD-1/PD-L1 Lead-like Library |
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy.
A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity.
Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.
|
|
83
|
| HY-50876 | Daporinad |
Daporinad (FK866) is a non-competitive inhibitor of nicotinamide phosphoribosyltransferase (Nampt), with a Ki value of 0.3 nM. Daporinad depletes NAD+ and ATP levels, inhibits mTORC1 and MAPK/ERK pathways, and activates TFEB to induce autophagy. Daporinad causes the depletion of the endoplasmic reticulum Ca²⁺ pool, ultimately weakening the mitogen-induced Ca²⁺ signal and the activation and function of T cells. Daporinad induces cell cycle arrest and apoptosis, and inhibits cell proliferation. Daporinad can be used for the study of myeloma, liver cancer, and immunosuppression.
|
|
67
|
| HY-B0389 | D-Glucose |
D-Glucose is the naturally occurring form of glucose and the most abundant monosaccharide. D-Glucose is a critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic or abiotic stress response.
|
Bacterial Infection
Cardiovascular Disease
Triple-Negative Breast Cancer
Metastatic Breast Cancer
Type 1 Diabetes
Type 2 Diabetes
|
63
|
| HY-P9902 | Pembrolizumab |
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
Species: Human |
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
HER-2 Positive Breast Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
37
|
| HY-15689 | Epacadostat |
Epacadostat (INCB 024360) is a potent and selective indoleamine 2,3-dioxigenase 1 (IDO1) inhibitor with an IC50 of 71.8 nM. Epacadostat can effectively reduce Trp metabolism, entailing increased activation and maturation of dendritic cells, and enhanced proliferation of effector T cells and natural killer cells (NKs), as well as attenuated Tregs expansion.
|
Inflammation or Immune System Disease
Prostate Cancer
Pancreatic Cancer
Viral Infection
SARS-CoV-2 Infection
|
28
|
| HY-125286 | AB-680 |
|
24
|
|
| HY-W011012 | Adenosine 5'-monophosphate disodium |
Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes.
|
|
22
|
| HY-13555 | β-Lapachone |
β-Lapachone (ARQ-501;NSC-26326) is a naturally occurring O-naphthoquinone, acts as a topoisomerase I inhibitor, and induces apoptosis by inhibiting cell cycle progression.
|
|
14
|
| HY-N0390S1 | L-Glutamine-13C5 |
L-Glutamine-13C5 is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
13
|
| HY-N0736 | Coptisine chloride |
Coptisine chloride is an alkaloid from Chinese goldthread, and acts as an efficient uncompetitive IDO inhibitor with a Ki value of 5.8 μM and an IC50 value of 6.3 μM. Coptisine chloride is a potent H1N1 neuraminidase (NA-1) inhibitor with an IC50 of 104.6?μg/mL and can be used for influenza A (H1N1) infection.
|
|
12
|
| HY-N0110 | Palmatine chloride |
Palmatine chloride is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC50s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine chloride can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC50 of 96 μM. Palmatine chloride shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities.
|
Neurological, Eye or Ear Disease
Metabolic or Endocrine Disease
Digestive System Disease
Leukemia/Lymphoma/Myeloma
Viral Infection
Bacterial Infection
Parasitic Infection
Digestive System Inflammation
|
11
|
| HY-W074143 | Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride |
Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride ([Ru(dpp)3]2+) is an electrochemiluminescent (ECL) probe and oxygen-sensitive sensor. Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride can be used to modify electrode surfaces for the detection of sulfates (S2O82-) and oxalates, based on electrochemical reactions that generate excited-state species, releasing photons through irreversible redox reactions. Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride utilizes the oxygen quenching of fluorescence mechanism, where fluorescence intensity reflects the metabolic rate of living microorganisms or oxygen levels within cells/tumors, allowing for real-time detection. Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride's main applications include microbial detection, antibacterial activity studies, and tumor microenvironment research.
|
|
11
|
| HY-16724 | Indoximod |
Indoximod (1-Methyl-D-tryptophan) is an orally active indoleamine 2,3-dioxygenase (IDO) pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR. Indoximod is an immunometabolic adjuvant used for the research of cancer.
|
|
11
|
| HY-16938 | 5'-Methylthioadenosine |
5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
|
Cancer
Metabolic or Endocrine Disease
Digestive System Disease
Parasitic Infection
Digestive System Inflammation
|
10
|
| HY-107780A | Cyclic-di-GMP sodium |
Cyclic-di-GMP sodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP sodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP sodium can be used in cancer research.
Source: bacterial species |
|
9
|
| HY-107780 | Cyclic-di-GMP |
Cyclic-di-GMP is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP can be used in cancer research.
Source: bacterial species |
|
9
|
| HY-107780B | Cyclic-di-GMP diammonium |
Cyclic-di-GMP diammonium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP diammonium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP diammonium can be used in cancer research.
|
|
9
|
| HY-110382 | Cyclic-di-GMP disodium |
Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research.
|
|
9
|
| HY-101560 | Linrodostat |
Linrodostat (BMS-986205) is a selective and irreversible indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor with an IC50 value of 1.1 nM in IDO1-HEK293 cells. Linrodostat is well tolerated with potent pharmacodynamic activity in advanced cancers.
|
|
7
|
| HY-P99032 | Monalizumab |
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
Species: Human |
|
7
|
| HY-100747 | PSB-12379 |
PSB-12379, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human).
|
|
5
|
| HY-P1844 | Chemerin-9 (149-157) |
Chemerin-9 (149-157) is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) has anti-inflammatory activity. Chemerin-9 (149-157) stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) ameliorates Aβ1-42-induced memory impairmen. Chemerin-9 (149-157) regulates immune responses, adipocyte differentiation, and glucose metabolism.
|
|
4
|
| HY-N0327 | Lobetyolin |
Lobetyolin, a bioactive compound, is derived from Codonopsis pilosula. Lobetyolin has anti-inflammatory, anti-oxidative and xanthine oxidase inhibiting activities. Lobetyolin also induces the apoptosis via the inhibition of ASCT2-mediated glutamine metabolism. Lobetyolin is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
|
4
|
| HY-P1844A | Chemerin-9 (149-157) TFA |
Chemerin-9 (149-157) TFA is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) TFA has anti-inflammatory activity. Chemerin-9 (149-157) TFA stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) TFA ameliorates Aβ1-42-induced memory impairmen. Chemerin-9 (149-157) TFA regulates immune responses, adipocyte differentiation, and glucose metabolism.
|
|
4
|
| HY-N0390S9 | L-Glutamine-15N-1 |
L-Glutamine-15N-1 is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
4
|
| HY-B0923 | Danthron |
Danthron is a natural product extracted from the traditional Chinese medicine Salvia miltiorrhiza Bunge. Danthron functions in regulating glucose and lipid metabolism by activating AMPK.
|
Pancreatic Cancer
Viral Infection
Bacterial Infection
Pain
Digestive System Inflammation
Glucose Metabolism
SARS-CoV-2 Infection
Obesity
|
4
|
| HY-N0390S | L-Glutamine-15N |
L-Glutamine-15N is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
4
|
| HY-112537 | D-Glucose 6-phosphate |
D-Glucose 6-phosphate is a key central node metabolite in glucose metabolism. It serves as the initiating metabolite for glycolysis and the pentose phosphate pathway, as well as a substrate for glycogen synthesis. D-Glucose 6-phosphate acts as a metabolic stress signal, which activates the mTOR pathway to promote protein synthesis, especially when phosphoglucose isomerase (PGI) is inhibited, thereby participating in cardiac remodeling processes. D-Glucose 6-phosphate can be used in research related to non-insulin-dependent diabetes mellitus and heart failure.
|
|
4
|
| HY-112537A | D-Glucose 6-phosphate dipotassium |
D-Glucose 6-phosphate dipotassium is a key central node metabolite in glucose metabolism. It serves as the initiating metabolite for glycolysis and the pentose phosphate pathway, as well as a substrate for glycogen synthesis. D-Glucose 6-phosphate dipotassium acts as a metabolic stress signal, which activates the mTOR pathway to promote protein synthesis, especially when phosphoglucose isomerase (PGI) is inhibited, thereby participating in cardiac remodeling processes. D-Glucose 6-phosphate dipotassium can be used in research related to non-insulin-dependent diabetes mellitus and heart failure.
|
|
3
|
| HY-B1180 | Vinburnine |
Vinburnine ((-)-Eburnamonine; (-)-Vincamone) is an orally active, blood-brain barrier permeable immunomodulator and apoptosis inducer. Vinburnine drives the secretion of IL-24 by activating the P38/MAPK/ATF3 signaling axis. Vinburnine induces reactive oxygen species production and DNA damage in cancer cells, thereby inhibiting cancer cell proliferation, activating the apoptotic cascade, and enhancing CD8+ T cell function to remodel the tumor immune microenvironment. Vinburnine can be used in the research of diseases such as melanoma.
|
|
3
|
| HY-112537B | D-Glucose 6-phosphate sodium |
D-Glucose 6-phosphate sodium is a key central node metabolite in glucose metabolism. It serves as the initiating metabolite for glycolysis and the pentose phosphate pathway, as well as a substrate for glycogen synthesis. D-Glucose 6-phosphate sodium acts as a metabolic stress signal, which activates the mTOR pathway to promote protein synthesis, especially when phosphoglucose isomerase (PGI) is inhibited, thereby participating in cardiac remodeling processes. D-Glucose 6-phosphate sodium can be used in research related to non-insulin-dependent diabetes mellitus and heart failure.
|
|
3
|
| HY-N0427 | Phellodendrine |
Phellodendrine is an orally active plant alkaloid. Phellodendrine inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway.
|
Akt
NF-κB
AMPK
mTOR
PKC
STAT
Interleukin Related
p38 MAPK
COX
Reactive Oxygen Species (ROS)
Apoptosis
Autophagy
PI3K
MMP
|
2
|
| HY-133890 | Tauro-α-muricholic acid |
Tauro-α-muricholic acid (T-α-MCA) is a Taurine (HY-B0351)-conjugated primary Bile acid. Tauro-α-muricholic acid is a FXR antagonist with an IC50 of 28 µM. Tauro-α-muricholic acid attenuates other bile acid-activated FXR signaling. Tauro-α-muricholic acid can be used in the research of Alzheimer's disease, glucose metabolism, and lipid metabolism.
|
|
2
|
| HY-N0735 | Phellodendrine chloride |
Phellodendrine chloride is an orally active plant alkaloid. Phellodendrine chloride inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine chloride promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine chloride can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine chloride suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine chloride inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine chloride has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway.
|
Autophagy
Apoptosis
AMPK
mTOR
STAT
Interleukin Related
PKC
p38 MAPK
NF-κB
COX
Reactive Oxygen Species (ROS)
PI3K
Akt
MMP
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Parkinson's Disease
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
2
|
| HY-N6985 | Baccatin III |
Baccatin III is an orally available, selective inhibitor of the TGF-β1 signaling pathway and myeloid-derived suppressor cell (MDSC) activation. Baccatin III targets the AKT/STAT6 and Smad2/3 pathways, blocking TGF-β1-induced fibroblast differentiation and MDSC-mediated immunosuppression. Baccatin III exerts anti-inflammatory and anti-fibrotic effects by inhibiting macrophage activation and extracellular matrix deposition, and shows potential in the treatment of pulmonary fibrosis and cancer in terms of regulating the tumor immune microenvironment.
|
|
2
|
| HY-141521 | Amelenodor |
NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn's disease and ulcerative colitis.
|
|
2
|
| HY-119109 | Laminaran |
Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.
Source: Eisenia Bicyclis |
|
2
|
| HY-112253 | D-Fructose 1-phosphate |
D-Fructose 1-phosphate is a key intermediate metabolite in the fructose metabolic pathway. As a key signaling molecule linking fructose metabolism and glucose metabolic regulation, D-Fructose 1-phosphate acts as an allosteric modulator to counteract the inhibitory effect of the glucokinase-regulatory protein complex, thereby finely regulating the direction of hepatic glucose metabolism at the substrate level.
Source: Escherichia coli |
|
1
|
| HY-145334 | CD73-IN-5 |
CD73-IN-5 is a potent and selective non-nucleotide small molecule inhibitor of CD73 (IC50 = 19 nM).
|
|
1
|
| HY-B0389S15 | D-Glucose-13C2-4 |
D-Glucose-13C2-4 is the 13C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response.
|
|
1
|
| HY-13966S | 2-Deoxy-D-glucose-d1 |
2-Deoxy-D-glucose-d is the deuterium labeled 2-Deoxy-D-glucose. 2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on hexokinase.
|
|
1
|
| HY-N5084 | Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside |
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside is a TRPV1 antagonist and HDAC7 inhibitor. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside blocks TRPV1-mediated calcium influx, suppresses phosphorylation of p65, IκBα, p38, JNK, and ERK1/2, inhibiting NF-κB and MAPK signaling cascades. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside reduces production and gene expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside exhibits potent analgesic activity, elevates thermal pain threshold and mechanical pain threshold in murine models. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside restores CD8+ T cell infiltration into bladder cancer tumors and improves bladder cancer immunotherapy efficacy. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside can be used for the researches of painand bladder cancer.
|
|
1
|
| HY-N0390S5 | L-Glutamine-1-13C |
L-Glutamine-1-13C is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
1
|
| HY-128733 | Phenyl acetate |
Phenyl acetate is an endogenous metabolite and a metabolite of 2-phenylethylamine, which can be found in urine. Phenyl acetate regulates the metabolism of glutamine. In addition, Phenyl acetate can be used as a detection index for certain diseases, such as depression.
|
|
1
|
| HY-P3448 | Certepetide |
Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
|
|
1
|
| HY-16938S1 | 5'-Methylthioadenosine-d3 |
5'-Methylthioadenosine-d3 is the deuterium labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
|
|
1
|
| HY-P99039 | Oleclumab |
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity.
Species: Human |
|
1
|
| HY-P99742 | Mitazalimab |
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.
Species: Human |
|
1
|
| HY-W591424 | m-PEG2000-NHS ester |
m-PEG2000-NHS ester (mPEG2000-SC) is a reagent with both cell adhesion inhibition and peptide conjugation functions. The NHS ester group of m-PEG2000-NHS ester forms stable amide bonds with primary amine-containing molecules (e.g., the N-terminus of MMP-2-cleavable octapeptide) to generate mPEG-peptide intermediates for liposome surface modification. When m-PEG2000-NHS ester is immobilized on a cystamine-modified gold surface, it can construct an in vitro model for cell adhesion kinetic studies, and higher PEG density and thicker layers correlate with lower cell adhesion rates. m-PEG2000-NHS ester can synthesize MMP-2-responsive PEGylated lipid conjugates to achieve MMP-triggered dePEGylation in the tumor microenvironment. m-PEG2000-NHS ester can be used in studies related to colon cancer and other conditions.
|
|
1
|
| HY-N0819 | Raddeanin A |
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.
|
Colorectal Cancer
Leukemia/Lymphoma/Myeloma
Cancer Immunology
Digestive System Inflammation
Non-Small Cell Lung Cancer
Immunotherapy for Melanoma
Alzheimer's Disease
|
1
|
| HY-B0389S10 | D-Glucose-13C |
D-Glucose-13C is the 13C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response.
|
|
1
|
| HY-N0390S2 | L-Glutamine-d5 |
L-Glutamine-d5 is the deuterium labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
1
|
| HY-N0390S8 | L-Glutamine-15N2 |
L-Glutamine-15N2 is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
1
|
| HY-101111 | PF-06840003 |
PF-06840003 (EOS200271) is a highly selective, orally active and brain-penetrant IDO-1 inhibitor with IC50s of 0.41 μM, 0.59 μM, and 1.5 μM for hIDO-1, dIDO-1, and mIDO-1, respectively.
|
|
1
|
| HY-128733S | Phenyl acetate-d5 |
Phenyl acetate-d5 is the deuterium labeled Phenyl acetate. Phenyl acetate is an endogenous metabolite and a metabolite of 2-phenylethylamine, which can be found in urine. Phenyl acetate regulates the metabolism of glutamine. In addition, Phenyl acetate can be used as a detection index for certain diseases, such as depression.
|
|
/
|
| HY-P2472 | Orphan GPCR SP9155 agonist P550 (mouse, rat) |
Orphan GPCR SP9155 agonist P550 (mouse, rat) (26RFa (mouse, rat)), a member of the RFamide peptide family with orexigenic effect, is the cognate ligand of the mouse orphan receptor GPR103, also designated SP9155 or AQ27.
|
|
/
|
| HY-W016773S | 1,10-Decanediol-d20 |
1,10-Decanediol-d20 is the deuterium labeled 1,10-Decanediol. 1,10-Decanediol is a diol compound that can react with α-ketoglutarate (aKG) to generate polymeric microparticles (termed paKG MPs) for the sustained release of aKG, thereby promoting immunosuppressive regulation. Additionally, paKG MPs can bind to dendritic cells (DCs), reducing their glycolysis and mitochondrial respiration in vitro. These metabolic changes lead to the modulation of MHC-II and CD86 expression in DCs and alter the frequency of regulatory T cells (Tregs) as well as T-helper type 1/2/17 cells in vitro. 1,10-Decanediol can be used in research within the field of immunometabolism. can be used as a surfactant/stabilizer in the synthesis of nanomaterials.
|
|
/
|
| HY-P99723 | Manelimab |
|
/
|
|
| HY-16938R | 5'-Methylthioadenosine (Standard) |
5'-Methylthioadenosine (Standard) is the analytical standard of 5'-Methylthioadenosine. This product is intended for research and analytical applications. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis[1]. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis[2].
|
|
/
|
| HY-126169 | L-Glutamine amide |
L-Glutamine amide is a metabolite involved in glutamate metabolism.
|
|
/
|
| HY-P11739 | ZD2 peptide |
ZD2 peptide is an EDB-FN-binding peptide with a Kd value of 11 μM. ZD2 peptide binds specifically to the EDB protein fragment of extradomain B fibronectin, a tumor microenvironment biomarker. ZD2 peptide can be conjugated to imaging agents. ZD2 peptide can be used for the research of cancer.
|
|
/
|
| HY-P1184 | HNGF6A |
HNGF6A is a humanin analogue. HNGF6A increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A inhibits of ROS production during oxidative stress. HNGF6A can prevent endothelial dysfunction and atherosclerosis in vivo.
|
Neurological, Eye or Ear Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-N0390G | L-Glutamine (GMP) |
L-Glutamine GMP is L-Glutamine (HY-N0390) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
|
/
|
| HY-112537S2 | D-Glucose 6-phosphate-13C |
D-Glucose 6-phosphate-13C is 13C labeled D-Glucose 6-phosphate (HY-112537). D-Glucose 6-phosphate is a key central node metabolite in glucose metabolism. It serves as the initiating metabolite for glycolysis and the pentose phosphate pathway, as well as a substrate for glycogen synthesis. D-Glucose 6-phosphate acts as a metabolic stress signal, which activates the mTOR pathway to promote protein synthesis, especially when phosphoglucose isomerase (PGI) is inhibited, thereby participating in cardiac remodeling processes. D-Glucose 6-phosphate can be used in research related to non-insulin-dependent diabetes mellitus and heart failure.
|
|
/
|
| HY-N16818 | 9-epi-Blumenol C |
9-epi-Blumenol C is a C13-norisoprenoid (carotenoid derivative) compound with allelopathic and antifungal activities, and can regulate plant growth. The IC50 values ??of 9-epi-Blumenol C for watercress roots and hypocotyls are 2780 μM and 2240 μM, respectively, and for perennial ryegrass roots and coleoptiles are 3290 μM and 2950 μM, respectively. 9-epi-Blumenol C exhibits allelopathic activity through a mechanism involving direct inhibition of plant growth and degradation of arbuscular mycorrhizal fungi (AMF) colonization, thereby weakening nutrient uptake and stress resistance in neighboring plants. 9-epi-Blumenol C can be used in herbicide development and research related to plant competition mechanisms. 9-epi-Blumenol C can be obtained from the dried fallen leaves of Metasequoia glyptostroboides (a plant of the cypress family, genus Metasequoia) through extraction with 70% methanol and purification by ethyl acetate extraction.
|
|
/
|
| HY-N0735R | Phellodendrine chloride (Standard) |
Phellodendrine chloride (Standard) is the analytical standard of Phellodendrine chloride (HY-N0735). Phellodendrine chloride is an orally active plant alkaloid. Phellodendrine chloride inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine chloride promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine chloride can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine chloride suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine chloride inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine chloride has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway.
|
Reference Standards
Autophagy
mTOR
AMPK
Apoptosis
STAT
Interleukin Related
PKC
p38 MAPK
NF-κB
COX
Reactive Oxygen Species (ROS)
PI3K
Akt
MMP
|
/
|
| HY-W251598I | Sodium bicarbonate, meets analytical specification of Ph. Eur., BP, USP, FCC, E500 |
Sodium bicarbonate, meets analytical specification of Ph. Eur., BP, USP, FCC, E500 is an inorganic salt that is neutral to slightly alkaline and easily decomposes when exposed to moisture in the air. Sodium bicarbonate can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, medicine, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
|
|
/
|
| HY-P1813 | PSA1 (141-150) |
PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments.
|
|
/
|
| HY-16938S2 | 5'-Methylthioadenosine-13C5 |
5'-Methylthioadenosine-13C5 (5'-(Methylthio)-5'-deoxyadenosine-13C5) is the 13C--labeled 5'-Methylthioadenosine (HY-16938). 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
|
|
/
|
| HY-P992518 | Pumitamig (Mouse IgG2a) |
Pumitamig (Mouse IgG2a) is the Mouse IgG2a control antibody for Pumitamig (HY-P991097). Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
|
|
/
|
| HY-P11798 | P-Selectin binding peptide |
P‑Selectin binding peptide is a short peptide that specifically targets P‑selectin. P‑Selectin binding peptide binds with high affinity to P‑selectin, which is highly expressed on activated platelets, inflamed endothelium, and in the tumor microenvironment. P‑Selectin binding peptide is used for precise targeted delivery and intervention in inflammation, thrombosis, and tumors.
|
|
/
|
| HY-P992051 | Anti-CD103 Antibody (hCD103.01A) |
Anti-CD103 Antibody (hCD103.01A) is a monoclonal antibody targeting human CD103 and can be used in cancer immunotherapy and immunological research. Recommend Isotype Controls: human IgG1 kappa, Isotype Control (HY-P99001).
Species: Human |
|
/
|
| HY-N20707 | Castalagin |
Castalagin is an orally active natural product with multiple biological activities including antibacterial activity against bacteria and anti-leishmanial activity against Leishmania aethiopica. Castalagin exhibits inhibitory activity against PARP1 and DNA topoisomerase II, with an IC50 of 0.86 μM for bovine PARP1. Castalagin reduces poly (ADP-ribosyl) ation modification in cells. Castalagin binds to the cell envelope of Ruminococcus bromii, increases the ratio of CD8+/FOXP3+CD4+ T cells in the tumor microenvironment, and acts as a prebiotic to enhance the activity of anti-PD-1 therapy. Castalagin induces morphological changes in Leishmania aethiopica promastigotes and inhibits their proliferation. Castalagin inhibits PBP2a-mediated peptidoglycan layer stabilization, disrupts bacterial peptidoglycan assembly, and inhibits and disintegrates bacterial biofilms. Castalagin can be used in research related to diseases such as cancer, leishmaniasis, and bacterial infections.
|
|
/
|
| HY-W753201 | 5'-Methylthioadenosine-13C |
5'-Methylthioadenosine-13C (5'-(Methylthio)-5'-deoxyadenosine-13C) is the 13C-labeled 5'-Methylthioadenosine (HY-16938). 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
|
|
/
|
| HY-W011012R | Adenosine 5'-monophosphate disodium (Standard) |
Adenosine 5'-monophosphate (disodium) (Standard) is the analytical standard of Adenosine 5'-monophosphate (disodium). This product is intended for research and analytical applications. Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes.
|
|
/
|
| HY-W251598J | Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard |
Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard is an inorganic salt. Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard is widely used in the fields of food, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
|
|
/
|
| HY-P991634 | IBI-325 |
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research.
Species: Human |
|
/
|
| HY-P1184A | HNGF6A TFA |
HNGF6A TFA is a humanin analogue. HNGF6A TFA increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A TFA inhibits of ROS production during oxidative stress. HNGF6A TFA can prevent endothelial dysfunction and atherosclerosis in vivo.
|
Neurological, Eye or Ear Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-N2024B | Maltose solution, 20% in H2O |
Maltose solution, 20% in H2O is a 20% aqueous maltose solution. Maltose is a disaccharide composed of two glucose molecules linked together. Maltose is an endogenous metabolic product in plants, yeast, or bacteria, and it participates in carbon source storage and metabolism. Maltose is a key core metabolite and main transport form in the temporary starch degradation, carbon output, and subsequent sucrose synthesis metabolism of the night chloroplast. In X. dendrorhous, maltose can act as a sugar donor and is converted into isomaltulose by α-glucosidase. Maltose can act as a osmotic agent, supporting continuous capillary ultrafiltration and preventing severe metabolic disorders.
|
|
/
|
| HY-20457G | TL8-506 (GMP) |
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy.
|
|
/
|
| HY-P10794 | LH2 peptide |
LH2 peptide is a pH-responsive cell-penetrating peptide dimer with the amino acid sequence LHHLCHLLHHLCHLAG. It can increase its uptake in tumor cells under weakly acidic conditions (such as the tumor microenvironment) through the protonation of histidine residues (pKa approximately 6). When conjugated with the anticancer drug Paclitaxel (HY-B0015), the PTX-LH2 conjugate showed superior tumor suppression effects compared to paclitaxel alone in a subcutaneous breast tumor model. The LH2 peptide holds potential as a drug delivery vehicle in cancer research.
|
|
/
|
| HY-P991309 | ZM-008 |
ZM-008 is an anti-LLT1 monoclonal antibody. ZM-008 blocks the interaction between LLT1 and CD161 on the surface of NK cells and T cells. ZM-008 restores anti-tumor immune activity, shifts the tumor microenvironment to an immune-responsive state, and recovers NK cell-mediated cytotoxicity against tumor cells, thereby reversing immunosuppression in immune-resistant "cold" tumors. ZM-008 is applicable to the research of immune-resistant solid tumors.
Species: Human |
|
/
|
| HY-P3448S | Certepetide-13C6,15N2 |
Certepetide-13C6,15N2 (CEND-1-13C6,15N2) is the 13C- and 15N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
|
|
/
|
| HY-128417AR | alpha-D-glucose hydrate (Standard) |
alpha-D-glucose (hydrate) (Standard) is the analytical standard of alpha-D-glucose (hydrate). This product is intended for research and analytical applications. alpha-D-glucose hydrate is a monosaccharide and the most common form of glucose. It is a monosaccharide, which means it cannot be broken down into simpler sugars. alpha-D-glucose plays a vital role in energy metabolism and is the primary source of energy for many cells in the body. It is also a building block of larger carbohydrates such as starch and glycogen. The "α" prefix refers to the orientation of the hydroxyl group attached to the first carbon atom. Alpha-D-glucose exists in solution as a hydrate, which means it is bound to water molecules.
|
|
/
|
| HY-16724R | Indoximod (Standard) |
Indoximod (Standard) is the analytical standard of Indoximod. This product is intended for research and analytical applications. Indoximod (1-Methyl-D-tryptophan) is an orally active indoleamine 2,3-dioxygenase (IDO) pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR. Indoximod is an immunometabolic adjuvant used for the research of cancer.
|
|
/
|
| HY-B1180R | Vinburnine (Standard) |
Vinburnine ((-)-Eburnamonine; (-)-Vincamone) (Standard) is the analytical standard of Vinburnine (HY-B1180). This product is intended for research and analytical applications. Vinburnine ((-)-Eburnamonine; (-)-Vincamone) phosphate is an orally active, blood-brain barrier permeable immunomodulator and apoptosis inducer. Vinburnine drives the secretion of IL-24 by activating the P38/MAPK/ATF3 signaling axis. Vinburnine induces reactive oxygen species production and DNA damage in cancer cells, thereby inhibiting cancer cell proliferation, activating the apoptotic cascade, and enhancing CD8+ T cell function to remodel the tumor immune microenvironment. Vinburnine can be used in the research of diseases such as melanoma.
|
|
/
|
| HY-P3448S1 | Certepetide-13C2,15N |
Certepetide-13C2,15N (CEND-1-13C2,15N) is the 13C- and 15N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
|
|
/
|
| HY-P991126 | Ciltistotug |
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy.
Species: Human |
|
/
|
| HY-P991125 | Cenzestotug |
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy.
Species: Human |
|
/
|
| HY-N6237 | Aspulvinone O |
Aspulvinone O is a selective inhibitor of glutamate oxaloacetate aminotransferase GOT1. Aspulvinone O inhibits glutamine metabolism and reduces NADPH production, thereby inducing oxidative stress and apoptosis in pancreatic ductal adenocarcinoma (PDAC) cells. Aspulvinone O inhibits PDAC cell proliferation in vitro and tumor growth in xenograft models.
Source: Aspergillus terreus |
|
/
|
| HY-P4116A | pH-Low Insertion Peptide TFA |
pH-Low Insertion Peptide TFA (pHLIP TFA) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide TFA targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide TFA successfully modifys polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide TFA -based targeting of cancer presents an opportunity to monitor metabolic changes and to selectively deliver imaging and therapeutic agents to tumors.
|
|
/
|
| HY-78131S3 | Ibuprofen-13C6 |
Ibuprofen-13C6 ((±)-Ibuprofen-13C6) is a 13C labeled Ibuprofen (HY-78131). Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers.
|
|
/
|
| HY-P992201 | Anti-CD160 Antibody (MAT 302) |
Anti-CD160 Antibody (MAT 302) (CL1-R2) is a human monoclonal antibody targeting CD160. Anti-CD160 Antibody (MAT 302) blocks the CD160-HVEM protein interaction, inhibits FGF2-mediated renal tubular vascular growth, and induces endothelial cell apoptosis. Anti-CD160 Antibody (MAT 302) targets CD160 on neovascularization to exert anti-angiogenic and vascular normalization effects, trigger the production of IFN-γ, TNF and IL-6 by NK cells, and enhance glucose metabolism of NK cells through the AKT/mTOR/s6k signaling pathway. Anti-CD160 Antibody (MAT 302) reduces vascular density, normalizes remaining tumor blood vessels, and inhibits tumor growth in melanoma-bearing mice. Anti-CD160 Antibody (MAT 302) can be used in research related to neovascularization, proliferative diabetic retinopathy, and melanoma.
Species: Human |
|
/
|
| HY-W654139 | 5'-Deoxy-5'-(methylthio)adenosine-d3 |
5'-Deoxy-5'-(methylthio)adenosine-d3 is deuterium labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
|
|
/
|
| HY-P10217 | PD-1/PD-L1-IN-42 |
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC50 of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Ovarian Cancer
|
/
|
| HY-13966S2 | 2-Deoxy-D-glucose-13C |
2-Deoxy-D-glucose-13C is the 13C labeled 2-Deoxy-D-glucose. 2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on hexokinase.
|
|
/
|
| HY-167805 | D-Glucose 6-phosphate potassium |
D-Glucose 6-phosphate potassium is a biologically active compound that has the activity of being a substrate for glucose-6-phosphate isomerase. D-Glucose 6-phosphate potassium can participate in the sugar metabolism process and promote the production and utilization of energy in cells.
|
|
/
|
| HY-B0389S29 | D-Glucose-18O |
D-Glucose-18O is the 18O labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules
|
|
/
|
| HY-16938S | 5'-Methylthioadenosine-13C6 |
5'-Methylthioadenosine-13C6 is the 13C-labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
|
|
/
|
| HY-N8389 | Globulol |
Globulol is a terpenoid metabolite and Antimicrobial agent. Globulol can be isolated from Alpinia oxyphylla Miq. Globulol binds to PAK4, reduces the expression level of PAK4 in cancer cells, decreases the phosphorylation of AKT, and downregulates the expressions of STAT3, phosphorylated STAT3, and PD-L1. Globulol promotes the secretion of CCL4 by cancer cells. Globulol reduces the viability and proliferation ability of cancer cells, induces G0/G1 cell cycle arrest and Apoptosis in cancer cells, and inhibits cancer cell migration and the integrity of 3D tumor spheres. Globulol enhances the relevant effects of anti-PD-1 agents in the cancer cell microenvironment. Globulol exhibits anticancer activity against liver cancer. Globulol inhibits the mycelial growth of phytopathogenic fungi and the growth of phytopathogenic bacteria. Globulol can be used in studies related to hepatocellular carcinoma.
|
|
/
|
| HY-176785S | MCB-294 |
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with Kds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC50s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRASG12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer.
|
|
/
|
| HY-103695 | CD73-IN-1 |
|
/
|
|
| HY-P10862A | AH-D peptide TFA |
AH-D peptide TFA is an antiviral peptide that selectively disrupts membrane structures within the size range of exosomes, inducing T-EXO depletion and enhancing cancer immunotherapy.
|
|
/
|
| HY-N0390S3 | L-Glutamine-13C5,15N2,d5 |
L-Glutamine-13C5,15N2,d5 is the deuterium, 13C-, and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-N14001 | Naamidine J |
Naamidine J is an imidazole-type alkaloids discovered in a sponge. Naamidine J inhibits inflammation by binding to the protein CSE1L (KD = 5.41 μM). Namidine J significantly inhibits the expression of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, and upregulates anti-inflammatory factors such as CD206 and Arg-1. Namidine J inhibits PD-L1 and shows antitumor activity. Namidine J significantly reduces pulmonary tissue edema, inflammatory cell infiltration and cytokine storm in mice. Namidine J can be used for the research on the immune microenvironment of acute lung injury and tumors.
Source: Pericharax heteroraphis |
|
/
|
| HY-P3486 | GADGVGKSAL |
GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research.
|
|
/
|
| HY-B0389S1 | D-Glucose-d1 |
D-Glucose-d is the deuterium labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molec
|
|
/
|
| HY-P990704 | Rilvegostomig |
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer.
Species: Human |
|
/
|
| HY-P10862 | AH-D peptide |
AH-D peptide is a brain-penetrant antiviral agent disrupting highly curved lipid membranes. AH-D peptide exhibits broad-spectrum antiviral activity against ZIKV, Dengue virus, Chikungunya virus, yellow fever virus and Japanese encephalitis virus, with
IC50 values of 11.9, 12.5, 35.7, 206 and 136 nM, respectively. AH-D peptide reduces the viral load in the brain, suppresses inflammation, protects neurons, and does not damage the blood brain barrier. AH-D peptide restores antitumor immunity by decreasing circulating PD-L1+ exosomes, reducing intratumoral immunosuppressive cells (regulatory T cells, myeloid-derived suppressor cells), and enhancing T cell function. AH-D peptide inhibits membrane-enveloped viruses and cancer cell metastasis in vivo. AH-D peptide exhibits no immunogenicity and has negligible effects on normal tissues. AH-D peptide can be used for research in Zika virus and other mosquito-borne viruses, cancer immunotherapy and metastasis. |
|
/
|
| HY-P3487 | GAGGVGKSA |
GAGGVGKSA is a wild type KRAS G12D 9mer peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
|
|
/
|
| HY-N3387 | Licoricidin |
Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch, possesses anti-cancer activities. Licoricidin (LCD) inhibit SW480 cells (IC50=7.2 μM) by inducing cycle arrest, apoptosis and autophagy, and is a potential chemopreventive or chemotherapeutic agent against colorectal cancer. Licoricidin (LCD) inhibits Lung Metastasis by inhibition of tumor angiogenesis and lymphangiogenesis as well as changes in the local microenvironment of tumor tissues the anticarcinogenic effect. Licoricidin enhanced gemcitabine-induced cytotoxicity in Osteosarcoma (OS) cells by inactivation of the Akt and NF-κB pathways in vitro and in vivo. Licoricidin blocks UVA-induced photoaging via ROS scavenging, limits the activity of MMP-1, it can be considered as an active ingredient in new topically applied anti-ageing formulations.
|
|
/
|
| HY-128417A | alpha-D-glucose hydrate |
alpha-D-glucose hydrate is a monosaccharide and the most common form of glucose. It is a monosaccharide, which means it cannot be broken down into simpler sugars. alpha-D-glucose plays a vital role in energy metabolism and is the primary source of energy for many cells in the body. It is also a building block of larger carbohydrates such as starch and glycogen. The "α" prefix refers to the orientation of the hydroxyl group attached to the first carbon atom. Alpha-D-glucose exists in solution as a hydrate, which means it is bound to water molecules.
|
|
/
|
| HY-P99834 | Crefmirlimab |
Crefmirlimab (IAB22M2C; ImaginAb) is a humanized CD8-specific single-domain antibody. Conjugation of Crefmirlimab with radioisotopes (e.g., 89Zr) enables tumor immune infiltration assessment, autoimmune disease detection, and immunotherapy response monitoring. Crefmirlimab is applicable for cancer research.
Species: Human |
|
/
|
| HY-B0389S16 | D-Glucose-1-13C |
D-Glucose-1-13C is the 13C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response.
|
|
/
|
| HY-P10449 | M2 Peptide |
M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis.
|
|
/
|
| HY-N1420AR | Rhamnose monohydrate (Standard) |
Rhamnose monohydrate (Standard) is the analytical standard of Rhamnose monohydrate (HY-N1420A). Rhamnose monohydrate (L-Rhamnose monohydrate) is an orally active deoxysugar. Rhamnose monohydrate can inhibit levels of pro-inflammatory interleukin and matrix metalloproteinases (MMPs) in skin aging models. Rhamnose can promote the phosphorylation levels of PKA substrates and HSL in SVF-derived adipocytes, stimulating PKA signaling. Rhamnose monohydrate can act against obesity in mice by stimulating fat dopamine receptors and inducing thermogenesis. Rhamnose monohydrate shows anti-aging effects. Rhamnose monohydrate can be used in the study of Ehrlich’s solid tumors and sarcomas.
|
|
/
|
| HY-N0390S4 | L-Glutamine-5-13C |
L-Glutamine-5-13C is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-P10424 | OPBP-1 |
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Ovarian Cancer
|
/
|
| HY-P3488 | GADGVGKSA |
GADGVGKSA is a mutant KRAS G12D 9mer peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
|
|
/
|
| HY-128733R | Phenyl acetate (Standard) |
Phenyl acetate (Standard) is the analytical standard of Phenyl acetate. This product is intended for research and analytical applications. Phenyl acetate is an endogenous metabolite and a metabolite of 2-phenylethylamine, which can be found in urine. Phenyl acetate regulates the metabolism of glutamine. In addition, Phenyl acetate can be used as a detection index for certain diseases, such as depression.
|
|
/
|
| HY-131303 | Heptadecanoyl Coenzyme A |
Heptadecanoyl Coenzyme A (Heptadecanoyl-CoA), long-chain acyl-coenzymes A (acyl-CoAs) (LCACoA), is an intermediate in lipid metabolism. Heptadecanoyl Coenzyme A can be used for the research of glucose metabolism.
|
|
/
|
| HY-P3102 | GLP-1(32-36)amide |
GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice.
|
|
/
|
| HY-P4588 | (Glu17,21,24)-Osteocalcin (1-49) (human) |
(Glu17,21,24)-Osteocalcin (1-49) (human) is a bone-specific protein involved in bone formation and glucose metabolism.
|
|
/
|
| HY-P990263 | Anti-Mouse CD73 Antibody (TY/23) |
Anti-Mouse CD73 Antibody (TY/23) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD73. Anti-Mouse CD73 Antibody (TY/23) can neutralize CD73. Anti-Mouse CD73 Antibody (TY/23) can be used for the researches of cancer, infection and immunology, such as B16F10 tumor and murine cytomegalovirus infection.
Species: Mouse |
|
/
|
| HY-156622 | Leramistat |
Leramistat (HMC-C-01-A; MBS2320) is a mitochondrial complex 1 inhibitor, involving in cell metabolism immune metabolism regulation. Leramistat also inhibits ATP production in Thp1 human monocytes (IC50: 0.63 μM). Leramistat inhibits atopic dermatitis and other skin diseases autoimmune diseases, inflammatory diseases, cancer; and also inhibits osteoclast mediated disease.
|
|
/
|
| HY-B0389S5 | D-Glucose-d2 |
D-Glucose-d2 is the deuterium labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response.
|
|
/
|
| HY-112502 | MethADP |
MethADP is a specific CD73 inhibitor.
|
|
/
|
| HY-P11058 | OVA(250-264) |
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8+ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research.
|
|
/
|
| HY-P99181 | Mupadolimab |
Inflammation or Immune System Disease
Non-Small Cell Lung Cancer
Triple-Negative Breast Cancer
SARS-CoV-2 Infection
|
/
|
|
| HY-P99169 | Uliledlimab |
|
/
|
|
| HY-W016773 | 1,10-Decanediol |
1,10-Decanediol is a diol compound that can react with α-ketoglutarate (aKG) to generate polymeric microparticles (termed paKG MPs) for the sustained release of aKG, thereby promoting immunosuppressive regulation. Additionally, paKG MPs can bind to dendritic cells (DCs), reducing their glycolysis and mitochondrial respiration in vitro. These metabolic changes lead to the modulation of MHC-II and CD86 expression in DCs and alter the frequency of regulatory T cells (Tregs) as well as T-helper type 1/2/17 cells in vitro. 1,10-Decanediol can be used in research within the field of immunometabolism. can be used as a surfactant/stabilizer in the synthesis of nanomaterials.
|
|
/
|
| HY-126411 | Peonidin-3-O-galactoside chloride |
Peonidin-3-O-galactoside chloride is an anthocyanin with antioxidant properties and blood-brain barrier permeability. Peonidin-3-O-galactoside chloride inhibits pancreatic lipase, with an IC50 value of 23.2 μg/mL against porcine pancreatic lipase. Peonidin-3-O-galactoside chloride mediates neuroprotection, regulates glucose metabolism, protects cells from high glucose-induced damage, promotes glucose uptake and increases ATP production. Peonidin-3-O-galactoside (chloride) can be used in the research of obesity and neurodegenerative diseases.
|
|
/
|
| HY-W251598S | Bicarbonate-13C sodium |
Bicarbonate-13C sodium is the 13C-labeled Sodium bicarbonate (HY-Y0756). Sodium bicarbonate is an inorganic salt that is neutral to slightly alkaline and easily decomposes when exposed to moisture in the air. Sodium bicarbonate can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, medicine, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
|
|
/
|
| HY-P990651 | PY314 |
PY314 is a humanized antibody targeting TREM2. PY314 binds TREM2 on tumor-associated macrophages, depletes TREM2-high tumor-associated macrophages, reduces pro-tumorigenic M2 macrophage infiltration, increases CD8+ T cell, NK cell, and M1 macrophage infiltration, creates a proinflammatory tumor microenvironment, and promotes antitumor immune responseS. PY314 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, breast cancer, and advanced refractory solid tumors.
Species: Human |
|
/
|
| HY-P10950A | PD-L1 inhibitory peptide TFA |
PD-L1 inhibitory peptide TFA is an inhibitor targeting the PD-1/PD-L1 interaction. PD-L1 inhibitory peptide TFA inhibits the PD-1-mediated apoptosis signaling pathway, maintains the survival and activity of T cells, activates the anti-tumor effect of cytotoxic T lymphocytes, and significantly improves the survival rate of mice in fungal sepsis models. PD-L1 inhibitory peptide TFA can be used for research on sepsis, breast cancer and other related diseases, as well as immunotherapy.
|
|
/
|
| HY-P990042 | Gotistobart |
Gotistobart (ONC-392; BNT 316) is a humanized anti-CTLA-4 antibody with selective regulatory T cell depletion activity in the tumor microenvironment. Gotistobart can be used for the research of cancer, such as non-small cell lung cancer.
Species: Human |
|
/
|
| HY-B0158R | Cytidine (Standard) |
Cytidine (Standard) is the analytical standard of Cytidine. This product is intended for research and analytical applications. Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function.
In Vivo:Cytidine decreases glutamate/glutamine levels and induces earlier improvement of depressive symptoms.
|
|
/
|
| HY-W145496 | Laminaribiose |
Laminaribiose is a disaccharide consisting of two glucose molecules linked by a β-1,3-glycosidic bond. It is ubiquitous in the cell walls of various plants and is a hydrolyzate of the polysaccharide laminarin. Laminaribiose has various applications in biochemical research, especially as a substrate for enzymes involved in carbohydrate metabolism. In addition, it can be used as a carbon source and dietary supplement for certain microorganisms.
|
|
/
|
| HY-137874 | L-Glutamic γ-monohydroxamate |
L-Glutamic γ-monohydroxamate is an antitumor agent, inhibits cell proliferation. L-Glutamic γ-monohydroxamate selectively inhibits the uptake of L-histidine into microvascular endothelial cell. L-Glutamic γ-monohydroxamate, as a vanadium ligand, activates glucose uptake and metabolism, thus decreases the blood glucose levels in vivo.
|
|
/
|
| HY-P10131 | 3BP-3940 |
3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases.
|
|
/
|
| HY-P4116 | pH-Low Insertion Peptide |
pH-Low Insertion Peptide (pHLIP) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide successfully modify polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide-based targeting of cancer presents an opportunity to monitor metabolic changes, and to selectively deliver imaging and therapeutic agents to tumors.
|
|
/
|
| HY-W251598B | Sodium bicarbonate, for molecular biology |
Sodium bicarbonate, for molecular biology (Sodium hydrogen carbonate for molecular biolog; Soda bicarbonate for molecular biolog) is an inorganic salt. Sodium bicarbonate can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
|
|
/
|
| HY-B0389S6 | D-Glucose-d7 |
D-Glucose-d77 is the deuterium labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response.
|
|
/
|
| HY-Y0624 | 4-Pentenoic acid |
4-Pentenoic acid is a medium-chain unsaturated fatty acid. 4-Pentenoic acid has hypoglycemic and fatty acid oxidation inhibitory activities. 4-Pentenoic acid can affect blood glucose metabolism and energy metabolism through mechanisms such as inhibiting long-chain fatty acid oxidation, reducing gluconeogenesis, and promoting glucose utilization.
|
|
/
|
| HY-107202GL | Polyinosinic-polycytidylic acid (GMP Like) |
Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
|
|
/
|
| HY-P99118 | Serplulimab |
Serplulimab (HLX 10) is a humanized anti-PD-1 monoclonal antibody. Serplulimab can inhibit tumor growth, regulate the tumor microenvironment, and has anti-tumor activity. Serplulimab can be used in the research of cancer such as lung cancer and colon cancer.
Species: Human |
|
/
|
| HY-40146 | tert-Butyl 3-oxoazetidine-1-carboxylate |
tert-Butyl 3-oxoazetidine-1-carboxylate is a synthetic intermediate. tert-Butyl 3-oxoazetidine-1-carboxylate can be used in compound research and development targeting cancer and tuberculosis.
|
|
/
|
| HY-N0390S6 | L-Glutamine-13C5,15N2 |
L-Glutamine-13C5,15N2 is the 13C- and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-108743 | Insulin degludec |
Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.
|
|
/
|
| HY-112502C | MethADP triammonium |
|
/
|
|
| HY-P6292A | KS-133 TFA |
KS-133 TFA is a highly selective and potent antagonist of the vascular active enteropeptide receptor 2 (VIPR2) with IC50 values for Ca influx measurement and cAMP measurement of 24.8 nM and 500 nM, respectively. KS-133 TFA reverses the tumor-promoting M2 phenotype of tumor-associated macrophages to the anti-tumor M1 phenotype, alters the tumor immune microenvironment, and inhibits tumor growth. KS-133 TFA can be used for research on schizophrenia and cancer immune regulation.
|
|
/
|
| HY-P99175 | KWAR 23 |
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.
Species: Human |
|
/
|
| HY-N0390R | L-Glutamine (Standard) |
L-Glutamine (Standard) is the analytical standard of L-Glutamine (HY-N0390). This product is intended for research and analytical applications. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
Source: Human Blood, Breast Milk, Cerebrospinal Fluid (CSF), Feces, Saliva, Sweat, Urine |
Reference Standards
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-N0707 | (S)-Indoximod |
(S)-Indoximod (1-Methyl-L-tryptophan) is an inhibitor of indoleamine 2,3-dioxygenase (IDO) (Ki: 19 μM). (S)-Indoximod can be used for the research of cancer and neurological disease.
|
|
/
|
| HY-P99046 | Selicrelumab |
Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study.
Species: Human |
Colorectal Cancer
Metastatic Breast Cancer
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Pancreatic Ductal Adenocarcinoma
|
/
|
| HY-128748 | DL-Glyceraldehyde |
DL-Glyceraldehyde is a bioactive substance involved in cellular energy metabolism and a key intermediate in sugar metabolism pathways (such as glycolysis and gluconeogenesis). During glycolysis, DL-Glyceraldehyde is converted by enzymes into other metabolites to provide energy for cells; during gluconeogenesis, DL-Glyceraldehyde participates in the synthesis of glucose as a precursor. In the field of medical research, DL-Glyceraldehyde can be used to study diseases related to sugar metabolism, such as diabetes, tumors, etc
|
|
/
|
| HY-P1070A | Amylin, amide, human TFA |
Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent.
|
|
/
|
| HY-W251598C | Sodium bicarbonate, for cell culture |
Sodium bicarbonate, for cell culture (Sodium hydrogen carbonate for cell culture; Soda bicarbonate for cell culture) is an inorganic salt that is neutral to slightly alkaline and easily decomposes when exposed to moisture in the air. Sodium bicarbonate, for cell culture can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, medicine, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
|
|
/
|
| HY-P991097 | Pumitamig |
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
Species: Human |
|
/
|
| HY-134816 | D-Glucan |
D-Glucan is an orally effective Dectin-1 receptor immune activator with antioxidant properties (reducing TNF-α). D-Glucan activates macrophages and neutrophils to scavenge free radicals, inhibit oxidative stress and inflammatory responses, and improve insulin sensitivity. D-Glucan promotes glycolysis by enhancing the activity of the antioxidant enzyme glutathione, inhibiting gluconeogenesis and activating GK. D-Glucan can be used in the research of liver damage protection (antagonizing Acetaminophen (HY-66005) toxicity), radiation protection (synergistic with vitamin E) and diabetes (improving glucose metabolism).
|
|
/
|
| HY-P1070 | Amylin, amide, human |
Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent.
|
|
/
|
Targets/Pathways































































































































































































